Skip to main content

Table 1 Characteristics with malignant ovarian germ cell tumor patients

From: Nomograms to predict the prognosis in malignant ovarian germ cell tumors: a large cohort study

Variables Training cohort No. (%) External validation cohort No. (%) P-value
Total 1401 121  
Age (years)    0.066
  ≤ 27 942 (67.24%) 70 (57.85%)  
 28–38 304 (21.70%) 37 (30.58%)  
  ≥ 39 155 (11.06%) 14 (11.57%)  
Tumor size (mm)    0.863
  ≤ 130 533 (38.04%) 47 (38.84%)  
 131–175 367 (26.20%) 29 (23.97%)  
  ≥ 176 501 (35.76%) 45 (37.19%)  
FIGO Stage    0.537
 FIGO Stage I 964 (68.81%) 81 (66.94%)  
 FIGO Stage II 99 (7.07%) 12 (9.92%)  
 FIGO Stage III 264 (18.84%) 24 (19.83%)  
 FIGO Stage IV 74 (5.28%) 4 (3.31%)  
Laterality    0.482
 Only one side 1349 (96.29%) 119 (98.35%)  
 Both sides 48 (3.43%) 2 (1.65%)  
 Unkown 4 (0.29%) 0 (0.00%)  
Histological subtype    0.016
 Dysgerminoma 405 (28.91%) 38 (31.40%)  
 Yolk sac tumor 207 (14.78%) 19 (15.70%)  
 Teratocarcinoma 771 (55.03%) 63 (52.07%)  
 Non-gestational choriocarcinoma 18 (1.28%) 1 (0.83%)  
Grade    0.941
 Grade I 120 (8.57%) 9 (7.44%)  
 Grade II 172 (12.28%) 16 (13.22%)  
 Grade III 216 (15.42%) 18 (14.88%)  
 Grade IV 91 (6.50%) 6 (4.96%)  
 Unkown 802 (57.24%) 72 (59.50%)  
Surgery    0.117
 No 13 (0.93%) 3 (2.48%)  
 Local resection 724 (51.68%) 69 (57.02%)  
 Debulking or cytoreductive surgery or pelvic exenteration 664 (47.39%) 49 (40.50%)  
Radiation    0.559
 No 1391 (99.29%) 119 (98.35%)  
 Yes 10 (0.71%) 2 (1.65%)  
Chemotherapy    0.568
 No 593 (42.33%) 55 (45.45%)  
 Yes 808 (57.67%) 66 (54.55%)  
  1. FIGO Federation International of Gynecology and Obstetrics